Works by Spanggaard, Iben


Results: 16
    1

    Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023.

    Published in:
    Neuro-Oncology Practice, 2025, v. 12, n. 1, p. 34, doi. 10.1093/nop/npae082
    By:
    • Fougner, Vincent;
    • Urup, Thomas;
    • Poulsen, Hans Skovgaard;
    • Grunnet, Kirsten;
    • Westmose, Christina Yde;
    • Melchior, Linea Cecilie;
    • Larsen, Karen Bonde;
    • Højgaard, Martin;
    • Spanggaard, Iben;
    • Belcaid, Laila;
    • Rohrberg, Kristoffer Staal;
    • Lassen, Ulrik;
    • Hasselbalch, Benedikte;
    • Nørøxe, Dorte Schou
    Publication type:
    Article
    2

    Mapping MAGE-A4 expression in solid cancers for targeted therapies.

    Published in:
    Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1484182
    By:
    • Habigt, Christin;
    • Rottey, Sylvie;
    • Spanggaard, Iben;
    • Lopez, Juanita S.;
    • Garralda, Elena;
    • Calvo, Emiliano;
    • Bechter, Oliver;
    • Desai, Jayesh;
    • Galot, Rachel;
    • Gandhi, Leena;
    • Heil, Florian;
    • Rieder, Natascha;
    • Dimitrov, Ivan;
    • Quetglas, Iris Martinez;
    • Heichinger, Christian;
    • Keshelava, Nino;
    • Roller, Andreas
    Publication type:
    Article
    3

    Extensive genomic analysis in patients with KRAS-mutated solid tumors shows high frequencies of concurrent alterations and potential targets but has limited clinical impact.

    Published in:
    Acta Oncologica, 2022, v. 61, n. 12, p. 1499, doi. 10.1080/0284186X.2022.2156809
    By:
    • Jacobsen, Ida Christine;
    • Spanggaard, Iben;
    • Højgaard, Martin;
    • Belcaid, Laïla;
    • Qvortrup, Camilla;
    • Yde, Christina Westmose;
    • Schmidt, Ane Yde;
    • Nielsen, Finn Cilius;
    • Willemoe, Gro Linno;
    • Dam, Mikkel Seidelin;
    • Lassen, Ulrik;
    • Staal Rohrberg, Kristoffer
    Publication type:
    Article
    4
    5

    Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor).

    Published in:
    BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-13851-4
    By:
    • Marbach, Daniel;
    • Brouer-Visser, Jurriaan;
    • Brennan, Laura;
    • Wilson, Sabine;
    • Davydov, Iakov I.;
    • Staedler, Nicolas;
    • Duarte, José;
    • Martinez Quetglas, Iris;
    • Nüesch, Eveline;
    • Cañamero, Marta;
    • Chesné, Evelyne;
    • Au-Yeung, George;
    • Hamilton, Erika;
    • Lheureux, Stephanie;
    • Richardson, Debra L.;
    • Spanggaard, Iben;
    • Gomes, Bruno;
    • Franjkovic, Izolda;
    • DeMario, Mark;
    • Kornacker, Martin
    Publication type:
    Article
    6

    Modeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor (Adv. Healthcare Mater. 1/2022).

    Published in:
    Advanced Healthcare Materials, 2022, v. 11, n. 1, p. 1, doi. 10.1002/adhm.202270001
    By:
    • Rafaeva, Maria;
    • Horton, Edward R.;
    • Jensen, Adina R.D.;
    • Madsen, Chris D.;
    • Reuten, Raphael;
    • Willacy, Oliver;
    • Brøchner, Christian B.;
    • Jensen, Thomas H.;
    • Zornhagen, Kamilla Westarp;
    • Crespo, Marina;
    • Grønseth, Dina S.;
    • Nielsen, Sebastian R.;
    • Idorn, Manja;
    • Straten, Per thor;
    • Rohrberg, Kristoffer;
    • Spanggaard, Iben;
    • Højgaard, Martin;
    • Lassen, Ulrik;
    • Erler, Janine T.;
    • Mayorca‐Guiliani, Alejandro E.
    Publication type:
    Article
    7

    Modeling Metastatic Colonization in a Decellularized Organ Scaffold‐Based Perfusion Bioreactor.

    Published in:
    Advanced Healthcare Materials, 2022, v. 11, n. 1, p. 1, doi. 10.1002/adhm.202100684
    By:
    • Rafaeva, Maria;
    • Horton, Edward R.;
    • Jensen, Adina R.D.;
    • Madsen, Chris D.;
    • Reuten, Raphael;
    • Willacy, Oliver;
    • Brøchner, Christian B.;
    • Jensen, Thomas H.;
    • Zornhagen, Kamilla Westarp;
    • Crespo, Marina;
    • Grønseth, Dina S.;
    • Nielsen, Sebastian R.;
    • Idorn, Manja;
    • Straten, Per thor;
    • Rohrberg, Kristoffer;
    • Spanggaard, Iben;
    • Højgaard, Martin;
    • Lassen, Ulrik;
    • Erler, Janine T.;
    • Mayorca‐Guiliani, Alejandro E.
    Publication type:
    Article
    8

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
    By:
    • Harding, James J.;
    • Piha-Paul, Sarina A.;
    • Shah, Ronak H.;
    • Murphy, Jessica J.;
    • Cleary, James M.;
    • Shapiro, Geoffrey I.;
    • Quinn, David I.;
    • Braña, Irene;
    • Moreno, Victor;
    • Borad, Mitesh;
    • Loi, Sherene;
    • Spanggaard, Iben;
    • Park, Haeseong;
    • Ford, James M.;
    • Arnedos, Mónica;
    • Stemmer, Salomon M.;
    • de la Fouchardiere, Christelle;
    • Fountzilas, Christos;
    • Zhang, Jie;
    • DiPrimeo, Daniel
    Publication type:
    Article
    9

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
    By:
    • Harding, James J.;
    • Piha-Paul, Sarina A.;
    • Shah, Ronak H.;
    • Murphy, Jessica J.;
    • Cleary, James M.;
    • Shapiro, Geoffrey I.;
    • Quinn, David I.;
    • Braña, Irene;
    • Moreno, Victor;
    • Borad, Mitesh;
    • Loi, Sherene;
    • Spanggaard, Iben;
    • Park, Haeseong;
    • Ford, James M.;
    • Arnedos, Mónica;
    • Stemmer, Salomon M.;
    • de la Fouchardiere, Christelle;
    • Fountzilas, Christos;
    • Zhang, Jie;
    • DiPrimeo, Daniel
    Publication type:
    Article
    10

    A first-in-human study of the fibroblast activation protein–targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors.

    Published in:
    Science Translational Medicine, 2023, v. 15, n. 695, p. 1, doi. 10.1126/scitranslmed.abp9229
    By:
    • Melero, Ignacio;
    • Tanos, Tamara;
    • Bustamante, Mariana;
    • Sanmamed, Miguel F.;
    • Calvo, Emiliano;
    • Moreno, Irene;
    • Moreno, Victor;
    • Hernandez, Tatiana;
    • Martinez Garcia, Maria;
    • Rodriguez-Vida, Alejo;
    • Tabernero, Josep;
    • Azaro, Analia;
    • Ponz-Sarvisé, Mariano;
    • Spanggaard, Iben;
    • Rohrberg, Kristoffer;
    • Guarin, Ernesto;
    • Nüesch, Eveline;
    • Davydov, Iakov I.;
    • Ooi, Chiahuey;
    • Duarte, José
    Publication type:
    Article
    11

    ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling – a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.

    Published in:
    BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10632-9
    By:
    • Kringelbach, Tina;
    • Højgaard, Martin;
    • Rohrberg, Kristoffer;
    • Spanggaard, Iben;
    • Laursen, Britt Elmedal;
    • Ladekarl, Morten;
    • Haslund, Charlotte Aaquist;
    • Harsløf, Laurine;
    • Belcaid, Laila;
    • Gehl, Julie;
    • Søndergaard, Lise;
    • Eefsen, Rikke Løvendahl;
    • Hansen, Karin Holmskov;
    • Kodahl, Annette Raskov;
    • Jensen, Lars Henrik;
    • Holt, Marianne Ingerslev;
    • Oellegaard, Trine Heide;
    • Yde, Christina Westmose;
    • Ahlborn, Lise Barlebo;
    • Lassen, Ulrik
    Publication type:
    Article
    12
    13

    Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.

    Published in:
    NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-021-00251-7
    By:
    • Smyth, Lillian M.;
    • Batist, Gerald;
    • Meric-Bernstam, Funda;
    • Kabos, Peter;
    • Spanggaard, Iben;
    • Lluch, Ana;
    • Jhaveri, Komal;
    • Varga, Andrea;
    • Wong, Andrea;
    • Schram, Alison M.;
    • Ambrose, Helen;
    • Carr, T. Hedley;
    • de Bruin, Elza C.;
    • Salinas-Souza, Carolina;
    • Foxley, Andrew;
    • Hauser, Joana;
    • Lindemann, Justin P. O.;
    • Maudsley, Rhiannon;
    • McEwen, Robert;
    • Moschetta, Michele
    Publication type:
    Article
    14

    First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

    Published in:
    British Journal of Cancer, 2022, v. 126, n. 7, p. 1010, doi. 10.1038/s41416-021-01657-7
    By:
    • Robbrecht, Debbie;
    • Jungels, Christiane;
    • Sorensen, Morten Mau;
    • Spanggaard, Iben;
    • Eskens, Ferry;
    • Fretland, Signe Ø;
    • Guren, Tormod Kyrre;
    • Aftimos, Philippe;
    • Liberg, David;
    • Svedman, Christer;
    • Thorsson, Lars;
    • Steeghs, Neeltje;
    • Awada, Ahmad
    Publication type:
    Article
    15
    16